Implementation of precision medicine in clinical trials in thoracic oncology: Which are the hurdles?

Precision medicine quite likely will be implemented at a different pace than originally hypothesized, but it is definitely the way to move forward. Even from a medical oncology perspective, a clear understanding of the changes in a molecular pathway and the timely application of a diagnostic assay are critical steps to ultimately deliver a better treatment choice to each individual patient with non–small cell lung cancer. See also pages 4800‐7. [ABSTRACT FROM AUTHOR]